Immutep Ltd. has released a corporate presentation highlighting its leadership in LAG-3 immunotherapy. The company is focusing on four clinical-stage assets and a preclinical program aimed at combating cancer and autoimmune diseases. The presentation details their first-in-class lead clinical candidates, including Efti, a novel MHC II agonist showing strong efficacy and a favorable safety profile in multiple cancers. Additionally, Immutep is conducting a Phase III trial in collaboration with MSD, evaluating Efti in combination with KEYTRUDA and chemotherapy for first-line treatment of non-small cell lung cancer. Immutep maintains full commercial rights to Efti. The company has multiple collaborations with large pharma and leading institutions. Immutep reports a strong intellectual property portfolio and a solid financial position with cash and cash equivalents of approximately A$146.25 million as of March 2025. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.